{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:55:33Z","timestamp":1793382933467,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["179571"],"award-info":[{"award-number":["179571"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Priority Program"},{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"publisher","award":["PZ00P3-142411"],"award-info":[{"award-number":["PZ00P3-142411"]}],"id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"publisher","award":["BSSGI0_155851"],"award-info":[{"award-number":["BSSGI0_155851"]}],"id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human immunodeficiency virus type 1 (HIV-1) infection is treated with antiretroviral therapy (ART), usually consisting of 2\u20133 different drugs, referred to as combination ART (cART). Our recent randomized clinical trial comparing a switch to dolutegravir monotherapy with continuation of cART in early-treated individuals demonstrated sustained virological suppression over 48 weeks. Here, we characterize the longitudinal landscape of the HIV-1 reservoir in these participants, with particular attention to potential differences between treatment groups regarding evidence of evolution as a proxy for low-level replication. Near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing was applied to longitudinal peripheral blood mononuclear cell samples to assess proviral evolution and the potential emergence of drug resistance mutations (DRMs). Neither an increase in genetic distance nor diversity over time was detected in participants of both treatment groups. Single proviral analysis showed high proportions of defective proviruses and low DRM numbers. No evidence for evolution during dolutegravir monotherapy was found in these early-treated individuals.<\/jats:p>","DOI":"10.1093\/infdis\/jiad292","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T12:26:08Z","timestamp":1690460768000},"page":"907-918","source":"Crossref","is-referenced-by-count":13,"title":["Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks"],"prefix":"10.1093","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3076-2999","authenticated-orcid":false,"given":"Lisa","family":"J\u00f6rimann","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Tschumi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6822-1473","authenticated-orcid":false,"given":"Marius","family":"Zeeb","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Leemann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne D","family":"Schenkel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Neumann","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E","family":"Chaudron","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Zaheri","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Frischknecht","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Neuner-Jehle","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Kuster","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique L","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Grube","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kouyos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin J","family":"Metzner","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-6723","authenticated-orcid":false,"given":"Huldrych F","family":"G\u00fcnthard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich"},{"name":"Institute of Medical Virology, University of Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Swiss HIV Cohort Study (SHCS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"2023100319160664100_jiad292-B1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"2023100319160664100_jiad292-B2","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia","volume":"278","author":"Wong","year":"1997","journal-title":"Science"},{"key":"2023100319160664100_jiad292-B3","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","article-title":"Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection","volume":"95","author":"Chun","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023100319160664100_jiad292-B4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat Med"},{"key":"2023100319160664100_jiad292-B5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"2023100319160664100_jiad292-B6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/COH.0000000000000287","article-title":"Persistent HIV-1 replication during antiretroviral therapy","volume":"11","author":"Martinez-Picado","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"2023100319160664100_jiad292-B7","doi-asserted-by":"crossref","first-page":"E4987","DOI":"10.1073\/pnas.1308313110","article-title":"The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time","volume":"110","author":"Josefsson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023100319160664100_jiad292-B8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004010","article-title":"Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy","volume":"10","author":"Kearney","year":"2014","journal-title":"PLoS Pathog"},{"key":"2023100319160664100_jiad292-B9","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav2045","article-title":"No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: implications for HIV eradication","volume":"5","author":"Bozzi","year":"2019","journal-title":"Sci Adv"},{"key":"2023100319160664100_jiad292-B10","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023100319160664100_jiad292-B11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1 replication maintains the tissue reservoir during therapy","volume":"530","author":"Lorenzo-Redondo","year":"2016","journal-title":"Nature"},{"key":"2023100319160664100_jiad292-B12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41467-019-08431-7","article-title":"Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion","volume":"10","author":"Pinzone","year":"2019","journal-title":"Nat Commun"},{"key":"2023100319160664100_jiad292-B13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12985-019-1276-8","article-title":"The forces driving clonal expansion of the HIV-1 latent reservoir","volume":"17","author":"Liu","year":"2020","journal-title":"Virol J"},{"key":"2023100319160664100_jiad292-B14","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1073\/pnas.1522675113","article-title":"Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo","volume":"113","author":"Simonetti","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023100319160664100_jiad292-B15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.chom.2017.03.008","article-title":"Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape","volume":"21","author":"Pollack","year":"2017","journal-title":"Cell Host Microbe"},{"key":"2023100319160664100_jiad292-B16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"2023100319160664100_jiad292-B17","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.4156","article-title":"Defective proviruses rapidly accumulate during acute HIV-1 infection","volume":"22","author":"Bruner","year":"2016","journal-title":"Nat Med"},{"key":"2023100319160664100_jiad292-B18","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1038\/s41467-019-10884-9","article-title":"Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART","volume":"10","author":"Bachmann","year":"2019","journal-title":"Nat Commun"},{"key":"2023100319160664100_jiad292-B19","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2023100319160664100_jiad292-B20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003421","article-title":"Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial","volume":"17","author":"Sculier","year":"2020","journal-title":"PLoS Med"},{"key":"2023100319160664100_jiad292-B21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2023100319160664100_jiad292-B22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2023100319160664100_jiad292-B23","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023100319160664100_jiad292-B24","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"2023100319160664100_jiad292-B25","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/cid\/ciy1132","article-title":"Dolutegravir monotherapy versus dolutegravir\/abacavir\/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial","volume":"69","author":"Hocqueloux","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023100319160664100_jiad292-B26","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/ciy1131","article-title":"Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial","volume":"69","author":"Braun","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023100319160664100_jiad292-B27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","article-title":"Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV","volume":"3","author":"Dow","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2023100319160664100_jiad292-B28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad366","article-title":"Sustained viral suppression with dolutegravir monotherapy over 192 weeks in patients starting combination antiretroviral therapy during primary HIV infection (EARLY-SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial","author":"West","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023100319160664100_jiad292-B29","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/infdis\/jit311","article-title":"Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size","volume":"208","author":"Jain","year":"2013","journal-title":"J Infect Dis"},{"key":"2023100319160664100_jiad292-B30","doi-asserted-by":"crossref","first-page":"e13310","DOI":"10.1371\/journal.pone.0013310","article-title":"Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection","volume":"5","author":"Schmid","year":"2010","journal-title":"PLoS One"},{"key":"2023100319160664100_jiad292-B31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006112","article-title":"Early antiretroviral therapy is associated with lower HIV DNA molecular diversity and lower inflammation in cerebrospinal fluid but does not prevent the establishment of compartmentalized HIV DNA populations","volume":"13","author":"Oliveira","year":"2017","journal-title":"PLoS Pathog"},{"key":"2023100319160664100_jiad292-B32","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac107","article-title":"Dolutegravir monotherapy as maintenance strategy: a meta-analysis of individual participant data from randomized controlled trials","volume":"9","author":"Fournier","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023100319160664100_jiad292-B33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/infdis\/jiz094","article-title":"Viral diversity based on next-generation sequencing of HIV-1 provides precise estimates of infection recency and time since infection","volume":"220","author":"Carlisle","year":"2019","journal-title":"J Infect Dis"},{"key":"2023100319160664100_jiad292-B34","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/nar\/gku537","article-title":"Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations","volume":"42","author":"Giallonardo","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2023100319160664100_jiad292-B35","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/infdis\/jiy131","article-title":"No effect of pegylated interferon-alpha on total HIV-1 DNA load in HIV-1\/HCV coinfected patients","volume":"217","author":"Strouvelle","year":"2018","journal-title":"J Infect Dis"},{"key":"2023100319160664100_jiad292-B36","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkad240","article-title":"Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018","author":"Jaha","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2023100319160664100_jiad292-B37","author":"Schmutz","year":"2023"},{"key":"2023100319160664100_jiad292-B38","author":"National Center for Biotechnology Information"},{"key":"2023100319160664100_jiad292-B39","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/bioinformatics\/16.4.400","article-title":"Detecting hypermutations in viral sequences with an emphasis on G --&gt; A hypermutation","volume":"16","author":"Rose","year":"2000","journal-title":"Bioinformatics"},{"key":"2023100319160664100_jiad292-B40","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/nar\/gkh340","article-title":"MUSCLE: multiple sequence alignment with high accuracy and high throughput","volume":"32","author":"Edgar","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"2023100319160664100_jiad292-B41","doi-asserted-by":"crossref","first-page":"e9490","DOI":"10.1371\/journal.pone.0009490","article-title":"Fasttree 2\u2014approximately maximum-likelihood trees for large alignments","volume":"5","author":"Price","year":"2010","journal-title":"PLoS One"},{"key":"2023100319160664100_jiad292-B42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12977-017-0356-3","article-title":"Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup","volume":"14","author":"Bachmann","year":"2017","journal-title":"Retrovirology"},{"key":"2023100319160664100_jiad292-B43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/aid.2019.0214","article-title":"HIV proviral sequence database: a new public database for near full-length HIV proviral sequences and their meta-analyses","volume":"36","author":"Shao","year":"2020","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023100319160664100_jiad292-B44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2016.11.008","article-title":"Minvar: a rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing","volume":"240","author":"Huber","year":"2017","journal-title":"J Virol Methods"},{"key":"2023100319160664100_jiad292-B45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society\u2013USA panel","volume":"68","author":"G\u00fcnthard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023100319160664100_jiad292-B46","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/JVI.02139-15","article-title":"Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy","volume":"90","author":"Kearney","year":"2016","journal-title":"J Virol"},{"key":"2023100319160664100_jiad292-B47","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00122-22","article-title":"Deep sequencing analysis of individual HIV-1 proviruses reveals frequent asymmetric long terminal repeats","volume":"96","author":"Joseph","year":"2022","journal-title":"J Virol"},{"key":"2023100319160664100_jiad292-B48","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/COH.0000000000000737","article-title":"Technologies for HIV-1 drug resistance testing: inventory and needs","volume":"17","author":"Metzner","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2023100319160664100_jiad292-B49","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/QAD.0000000000002850","article-title":"Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation","volume":"35","author":"Li","year":"2021","journal-title":"AIDS"},{"key":"2023100319160664100_jiad292-B50","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1073\/pnas.86.7.2365","article-title":"Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone","volume":"86","author":"Folks","year":"1989","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad292\/51093021\/jiad292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/7\/907\/51840659\/jiad292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/7\/907\/51840659\/jiad292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:22:22Z","timestamp":1696346542000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/7\/907\/7232329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,27]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad292","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,7,27]]}}}